Loading
A phase 3 trial of Volrustomig in cervical cancer, run by AstraZeneca, now recruiting.
Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical) is a phase 3 interventional study registered as NCT06079671 by AstraZeneca, with 800 participants planned, started 2023-09-22 and due to reach its primary completion in 2027-11-26. Interventions recorded: Volrustomig.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Locally advanced cervical cancer, AstraZeneca, Cervical cancer and the tag pipeline.
Shares Locally advanced cervical cancer, Cervical cancer and the tag pipeline.
Shares AstraZeneca and the tag pipeline.
Shares AstraZeneca and the tag pipeline.
Shares AstraZeneca and the tag pipeline.
Shares AstraZeneca and the tag pipeline.
Shares AstraZeneca and the tag pipeline.
Shares Cervical cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/